2022 - EpiVax, Inc. - Informatics and Immunology

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

by Elena Iemma | Sep 22, 2023

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

by Elena Iemma | Sep 22, 2023

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

by Elena Iemma | Sep 22, 2023

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics… of Peptides and P-ANDAS

In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities

In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities

by Elena Iemma | Sep 21, 2023

In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Corey Iacono | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H

« Older Entries